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The skin barrier function has been attributed to the stratum corneum and represents a major challenge 
in clinical practice pertaining to cutaneous administration of drugs. Despite this, a large number of 
bioactive compounds have been successfully administered via cutaneous administration because of 
advances in the design of topical and transdermal formulations. In vitro and in vivo evaluations of these 
novel drug delivery systems are necessary to characterize their quality and efficacy. This review covers 
the most well-known methods for assessing the cutaneous absorption of drugs as an auxiliary tool for 
pharmaceutical formulation scientists in the design of drug delivery systems. In vitro methods as skin 
permeation assays using Franz-type diffusion cells, cutaneous retention and tape-stripping methods to 
study the cutaneous penetration of drugs, and in vivo evaluations as pre-clinical pharmacokinetic studies 
in animal models are discussed. Alternative approaches to cutaneous microdialysis are also covered. 
Recent advances in research on skin absorption of drugs and the effect of skin absorption enhancers, 
as investigated using confocal laser scanning microscopy, Raman confocal microscopy, and attenuated 
total reflectance Fourier-transform infrared spectroscopy, are reviewed.
Uniterms: Skin absorption/effects/study. Skin absorption/topical formulations. Skin absorption/
transdermal formulations. Skin absorptions/enhancers.
INTRODUCTION
Topical and transdermal drug delivery systems have 
shown significant advantages in clinical practice for drug 
targeting to the action site in the body; this has reduced 
the systemic side effects. The administration of drugs by 
through the skin is also performed to achieve controlled 
or prolonged drug delivery, and this route can be explored 
as an alternative to the oral route. The oral route shows 
some limitations for drugs with irregular absorption in the 
gastrointestinal tract and low bioavailability and for drugs 
with increased first pass metabolism and short plasma half-
life times (Barry, 2001; Wokovich et al., 2006; Prausnitz, 
Langer, 2009; Alexander et al., 2012).
Many drug products applied to the skin surface 
may penetrate to some extent into the skin layers, where 
their effects are expected. This is the case for topical 
formulations for treatment of skin disorders such as 
acne and cutaneous inflammatory diseases that include 
dermatitis, erythematous lupus, and psoriasis. On the 
other hand, transdermal formulations release drugs 
that permeate through the skin and enter the systemic 
circulation. Transdermal therapy must ensure that 
significant concentrations of the drug are absorbed to 
reach effective plasma concentrations. Permeation of 
drugs is targeted in some cases to body regions close to 
the action site, where a regional effect is expected, e.g., 
in the muscles, blood vessels, and articulations. In this 
way, the term “cutaneous absorption” is properly used to 
characterize the sum of the amounts of drug that penetrate 
and permeate the skin (Barry, 2001; El Maghraby, Barry; 
Williams, 2008; Williams, Barry, 2012; Selzer et al., 
2013).
Different methods have been proposed to evaluate 
the cutaneous absorption of drugs to optimize the 
development of novel formulations to be administered 
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through the skin. These methods are important tools 
for assessing the efficacy and quality of topical and 
transdermal formulations (Lin, Ho, Chien, 1993; 
Manadas, Pina, Veiga, 2002; Thakker, Chern, 2003; 
Valenta, Auner, 2004; Cardot, Beyssac, Alric, 2007; Frum 
et al., 2007; Chen, Han, Lian, 2013; Schwarz, Pagitsch, 
Valenta, 2013). However, pharmaceutical formulation 
scientists must be aware of all options in the selection 
of methods for intended formulations (Seki et al., 2004; 
Godin, Touitou, 2007; Zhang, Chan, Leong, 2013).
The aim of this study was to systematically review 
the in vitro and in vivo methods applied to the assessment 
of skin penetration and permeation of drugs from topical 
and transdermal formulations, with the goal of aiding the 
pharmaceutical formulation scientists in the selection 
of the most appropriate formulation for a particular 
investigation.
Drug transport across the skin
The skin is the largest organ of the human body and 
has a surface area of  about 2 m2 in healthy adults (Groeber 
et al., 2011). It is a heterogeneous multilayer tissue, and its 
primary function is to protect the body from the external 
environment by functioning as an effective barrier to 
absorption of exogenous molecules (Godin, Touitou, 
2007; Darlenski et al., 2009; Prausnitz, Langer, 2009; 
Williams, Barry, 2012; Anissimov et al., 2013; Jepps et 
al., 2013). The epidermis and dermis layers form the main 
skin structure (Figure 1).
The dermis thickness ranges from 3 to 5 mm and 
consists of a mixture of fibrous proteins (collagen and 
elastin) and an interfibrillar gel of glycosaminoglycans, 
salts, and water. Collagen types I and II account for 
approximately 75% of the dry weight of the dermis. Blood 
and lymph vessels, free nerve endings, hair follicles, and 
sebaceous and sweat glands are embedded in the dermis. 
The hair follicles and sweat gland ducts open directly to 
the outside on the surface of the skin (Caspers et al., 1998; 
Moser et al., 2001; El Maghraby, Barry, Williams, 2008; 
Cevc, Vierl, 2010; Notman, Anwar, 2013; Mathes, Ruffner, 
Graf-Hausner, 2014).
The epidermis, excluding the stratum corneum, 
which is its outermost layer, is a viable tissue. The 
epidermis does not have vascularization, and nutrients 
diffuse from the dermoepidermal junction to maintain its 
viability. There are five layers that represent the different 
stages of cell life in the epidermis. The sequence of layers 
from inside to outside are the germinative (or basal) layer, 
stratum spinosum, stratum granulosum, stratum lucidum, 
and stratum corneum (Karadzovska et al., 2013; Notman, 
Anwar, 2013; Mathes, Ruffner, Graf-Hausner, 2014).
The stratum corneum cells are called corneocytes. 
These cells are dense, functionally dead, anucleated, and 
filled with keratin. The stratum corneum arrangement 
is analogous to a wall of “bricks and mortar” in that 
corneocytes represent the bricks and the intercellular 
lipids represent the mortar. The lipids form several 
bilayers surrounding the corneocytes. The intercellular 
lipid consists of a mixture of ceramides, cholesterol, 
cholesterol esters, fatty acids, and a small fraction of 
cholesterol sulfate (Barry, 2001; EL Maghraby, Barry, 
Williams, 2008; Anissimov et al., 2013; Jepps et al., 
2013). The stratum corneum contains 15 to 20 layers 
of corneocytes, and, in its dry state, has a thickness 
of 10 to 15 µm. When hydrated, the stratum corneum 
considerably swells, and its thickness may reach up to 40 
µm, showing an increased permeability. Considering its 
barrier characteristics and water resistance, the stratum 
corneum is the main layer that limits drug absorption 
through the skin (El Maghraby, Barry, Williams, 2008; 
Cevc, Vierl, 2010; Anissimov et al., 2013; Jepps et al., 
2013). Andrews and co-workers (2013) observed that 
removal of the stratum corneum drastically increased 
skin permeability, whereas removal of the full epidermis 
increased skin permeability by 1 to 2 orders of magnitude. 
Therefore, different skin layers influence permeability 
but at different magnitudes.
The skin permeation routes include transport across 
the epidermis and skin appendages, particularly the 
hair follicles and sweat glands that form an alternative 
pathway to the intact epidermis. The skin appendages 
represent only 0.1% of the total surface of the human 
skin and the contribution of this route for permeation 
FIGURE 1 - Normal human skin.
Evaluation of skin absorption of drugs from topical and transdermal formulations 529
flux of drugs is small. Recently, it was proposed that the 
route through the skin appendages contributes little to 
the rate of skin absorption of most drugs in the steady 
state; however, this route enables permeation of charged 
molecules and large polar compounds; e.g., peptide-based 
drugs. The major route of skin permeation is through 
the intact epidermis, and two main pathways have been 
identified: the intercellular route through the lipids of the 
stratum corneum and the transcellular route through the 
corneocytes. In both cases, the drug must diffuse into the 
intercellular lipid matrix, which is recognized as the major 
determinant of drug absorption by the skin (Alexander 
et al., 2012; Desai et al., 2013; Frasch, Barbero, 2013; 
Notman, Anwar, 2013).
According to Kalia and Guy (2001), drug transport in 
the skin is a process involving several steps: a) dissolution 
and release of drug from the formulation; b) drug 
partitioning into the stratum corneum; c) drug diffusion 
across the stratum corneum, mainly by intercellular lipids; 
d) drug partitioning from the stratum corneum into viable 
epidermis layers; e) diffusion across the viable epidermis 
layers into the dermis, and f) drug absorption by capillary 
vessels, which achieves systemic circulation (Kalia, Guy, 
2001).
The choice of drug candidates for permeation 
through the skin must be based on several factors, 
including physicochemical properties, drug interactions 
with the membrane, and pharmacokinetic considerations. 
The ideal physicochemical properties of a drug selected 
for cutaneous administration are low molecular weight 
(<600 Da) because the diffusion coefficient will be high; 
solubility in water and oils to achieve a high concentration 
gradient and increase the diffusion force across the 
skin; an elevated but balanced partition coefficient 
because very high partition coefficients may inhibit drug 
clearance from the skin and increase drug retention; and 
a low melting point (<200 ºC), which is related to an 
appropriate solubility (Kalia, Guy, 2001; Moser et al., 
2001; Farahmand, Maibach, 2009; Williams, Barry, 2012; 
Delgado-Charro, Guy, 2014).
In vitro evaluation of the skin permeation of 
drugs
In vitro  methods enable precise control of 
experimental variables by using the simplest protocols. 
However, in vitro assays cannot fully reproduce the 
complexity of biological systems, and in vivo evaluations 
are recommended to validate the results and, if possible, 
establish an in vivo–in vitro correlation. Nevertheless, in 
vitro evaluations are essential tools for the development 
and screening of formulations, predicting in vivo cutaneous 
absorption (Thakker, Chern, 2003; Cardot, Beyssac, Alric, 
2007; Frum et al., 2007; Godin, Touitou, 2007; Yang et 
al., 2015).
The diffusion cell  is the most widely used 
experimental apparatus to assess the release and 
skin permeation of drugs incorporated in topical and 
transdermal drug delivery systems. The main objective 
of these assessments lies in identifying the main variables 
during formulation design that may alter the in vivo 
bioavailability of the drug (Lewis, Paulo, Faustino, 
1997; Brown et al., 2004; Godin, Touitou, 2007; Cevc, 
Vierl, 2010; Hanson, 2010). The first work in this field 
was developed by Thomas J. Franz in 1970. The basic 
configuration of the experimental apparatus is composed 
of a) the donor compartment, wherein the formulation is 
applied to a semipermeable membrane where the drug 
released must permeate, and b) a receiver chamber, 
wherein samples can be withdrawn for drug analysis 
(Moser et al., 2001; Leveque et al., 2004; Hanson, 2010).
The vertical diffusion cell is a modification of the 
original Franz diffusion cell. This apparatus has been 
used to evaluate different formulations, such as gels, 
creams, ointments, and patches (Thakker, Chern, 2003; 
Hanson, 2010). Different configurations of this diffusion 
cell are commercially available and have different volume 
capacities in the receiver chamber (4, 7, and 12 mL) and 
effective diffusion areas (1.77 and 2.54 cm2). The scheme 
of the vertical diffusion cell is shown in Figure 2.
The experimental conditions for assessment of skin 
permeation include a receptor medium maintained under 
constant magnetic stirring and temperature. Important 
considerations must be highlighted; e.g., the composition 
of the medium must assure sink conditions because the 
drug concentration must not reach values  >10% of its 
saturation (Azarmi, Roa, Löbenberg, 2007). For this, the 
drug must be freely soluble in the receptor medium. The 
sink conditions are an essential presupposition so that the 
FIGURE 2 -Vertical diffusion cell (Reproduced with permission 
from Wiley-Scrivener from Ruela, Pereira, 2017).
A. L. M. Ruela, A. G. Perissinato, M. E. S. Lino, P. S. Mudrik, G. R. Pereira530
drug concentration in the receptor medium does not limit 
the permeation rate. The recommended receptor media are 
aqueous buffers related to the physiological environment. 
The use of additives in the receptor medium is necessary 
in some cases to increase the drug’s solubility, but these 
additives should not compromise the integrity of the 
membrane or alter the drug’s permeability. Some additives 
incorporated in the medium are non-ionic surfactants 
(e.g., Tween 80), bovine serum albumin, polyethylene 
glycol, and ethanol. To prevent microbiological growth 
in the medium, preservatives may be added, such 
as gentamicin, sodium azide (0.02%-0.05%) and 
formaldehyde (0.1%). Selective analytical techniques are 
used for appropriate separation of contaminants from the 
skin, formulation, or receptor medium. High-performance 
liquid chromatography (HPLC) is recommended for drug 
quantification (Siewert et al., 2003; Thakker, Chern, 2003; 
Wang, Ma, Higgins, 2006; Hanson, 2010; Ruela et al., 
2013; Selzer et al., 2013).
The Keshary-Chien cell is an experimental apparatus 
for evaluation of poorly water-soluble drugs, which 
assures sink conditions. The apparatus has the same 
configuration as that of the vertical diffusion cell; however, 
it can increase the homogeneity of larger volumes (>15 
mL) of the receptor medium (Tojo, Keshary, Chien, 1986). 
The flow-through cell is another experimental apparatus 
indicated for evaluation of poorly water-soluble drugs. In 
this apparatus, the medium is perfused in a constant flow 
rate by using a peristaltic pump. The flow-through cell is 
usually applied to assure sink conditions, but drug dilution 
in the receptor medium may require a sensible analytical 
method for its quantification (Gupta, Jain, Varshney, 2005; 
Choi et al., 2012; Selzer et al., 2013).
The diffusion cell can be modified to evaluate 
transdermal formulations on the basis of iontophoresis. 
Iontophoresis is a physical process for enhancing drug 
permeation through the skin by applying an electric field. 
The diffusion cells are adapted with silver–silver chloride 
electrodes in the donor chamber for application of a 
current on the skin surface. The formulations are prepared 
in an aqueous vehicle, such as hydrogels, and the drug 
is ionized. The drug diffusion is driven by the electro-
osmotic flow due to the electric field (Gratieri, Gelfuso, 
Lopez, 2008; Alexander et al., 2012; Patni et al., 2012; 
Gratieri, Kalia, 2013; Saluja et al., 2013).
The United States Pharmacopeia apparatus II 
(paddle) is less used for evaluating skin permeation of 
drugs. This assay employs a glass cylindrical tube closed 
on one side of its border with excised skin, with stratum 
corneum inside. The formulation is placed into the 
cylindrical tube over the , stratum corneum, and the dermis 
side is submerged into the receptor medium. Samples of 
the medium are withdrawn at different times for drug 
quantification (Fouad et al., 2013).
Whole skin or dermatomed tissues have been used 
for in vitro permeation assays. The dermatomization 
technique standardizes the thickness of the skin, but it has 
been associated with increased skin permeations by the 
follicular route because of the opening of the bottom of the 
follicles. On the other hand, when the whole skin is used, 
the dermis layer may take up water because of swelling 
of this layer. In this case, drug diffusion is decreased and 
drug retention in the dermis may be increased (Moser et 
al., 2001; Alexander et al., 2012; Selzer et al., 2013). 
The most relevant model for evaluation of in vitro 
skin absorption of drugs is human skin excised from 
cadavers or obtained from plastic surgeries. However, the 
availability of human skin is limited, and animal models 
are often employed. The skin from animal models is highly 
recommended for preliminary evaluations in the screening 
of novel formulations. The animal models used to replace 
human skin are domestic pigs, rats, mice, guinea pigs, and 
snakes (Nair et al., 1997; Zorin, Kuylenstierna, Thulin, 
1999; Nair et al., 2013). According to Godin and Touitou 
(2007), the porcine ear skin has shown results comparable 
to those of normal human skin (Godin, Touitou, 2007). 
Studies examining the thickness of various skin layers 
have shown that pig ear skin has a thickness similar to 
that of human skin (stratum corneum and epidermis). The 
follicular structure, vascular anatomy, and arrangement 
of collagen fibers in the dermis of the pig ear, as well as 
the content of glycosphingolipids and ceramides, are also 
similar to those of the human skin (Nair et al., 1997; Zorin, 
Kuylenstierna, Thulin, 1999; Heard et al., 2006; Klang et 
al., 2012; Chen, Han, Lian, 2013; Delgado-Charro, Guy, 
2014).
Skin permeation studies using inadequate protocols 
generate inaccurate data (Godin, Touitou, 2007). 
Thus, selection of the protocol must be performed by 
using experimental conditions, such as skin model, 
experimental  apparatus,  and receptor medium, 
appropriate for the formulation to be evaluated, and it 
must be based on the physicochemical properties of 
the drug, including aqueous solubility and oil-water 
partition coefficients. Several recent studies have 
focused on development of transdermal devices for 
administration of donepezil, an anti-Alzheimer drug 
(Choi et al., 2012; Subedi et al., 2012; Saluja et al., 2013; 
Liu et al., 2014). In these studies, the permeation of this 
lipophilic compound (log P > 4) was studied by using 
different experimental protocols, including skin models, 
experimental apparati, and formulations. Choi and co-
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workers (2012) demonstrated a 1-fold reduction in the 
results of donepezil permeation by using human cadaver 
skin relative to the results of studies using hairless mouse 
skin, a skin model with increased permeability. The 
permeation of donepezil was also studied by Liu et al. 
(2014) who used rabbit abdominal skin and by Subedi 
and co-workers (2012) who used isolated hairless mouse 
skin. These authors also achieved satisfactory results 
by using these skin models; however, the amounts of 
drug permeated were overestimated in relationship 
to permeation across normal human skin. Different 
experimental apparati were applied with satisfactory 
results to evaluate the skin permeation of donepezil from 
different formulations, including the Keshary–Chien 
cell (Choi et al., 2012) and flow-through cell (Subedi et 
al., 2012). In all cases, an important point is to perform 
in vitro screening of drug permeation from different 
formulations and identify the factors that increase the 
transdermal flux of the drugs to predict their in vivo 
behavior from different drug delivery systems.
Some experimental conditions for studying in 
vitro skin permeation were selected and are shown in 
the Table I. There was a huge number of experimental 
conditions in the selected studies using skin permeation 
assays, including the skin model, composition of receptor 
medium, and type of diffusion cell. Comparison of skin 
permeation data from different studies is not a simple task, 
and permeation data must be analyzed to determine the 
effects of the formulations under the same experimental 
conditions. In this way, it is possible to identify the 
variables in formulations that increase drug flux through 
the skin as a way to select promising formulations for 
evaluation in clinical trials.
For analysis of the permeation data, the amounts 
of drug permeated are plotted against the time. In many 
cases, an excess of drug is applied to the skin surface 
(infinite dose), and its depletion is negligible. In these 
cases, drug permeation follows zero-order kinetics, which 
characterizes the drug diffusion across the skin according 
to Fick’s law. In these cases, a linear equation is calculated 
in the steady state, and its inclination represents the flux of 
drug across the skin, also denominated as the permeation 
rate. In contrast, when a finite dose of drug is applied to the 
skin, the relationship between amounts of drug permeated 
and time is not linear. When the drug amounts applied to 
the skin decrease along the time, the permeation rate is also 
decreased. Drug flux through the skin under non-saturated 
conditions follows pseudo-zero order kinetics (or Higuchi 
kinetics), in which the drug concentration is proportional 
to the square root of time (Moser et al., 2001; Selzer et 
al., 2013).
Evaluating the penetration of drugs into the skin
The evaluation of penetration of drugs into the 
skin is important in development of topical formulations 
because the expected effect is targeted to the superficial 
layers of the skin. The concentrations of drug in the skin 
layers can be determined by in vitro and in vivo assays, 
such as by conducting cutaneous retention studies and by 
using the tape-stripping technique (Moser et al., 2001; 
Yamashita, Hashida, 2003; Naegel, Heisig, Wittum, 2013; 
Nair et al., 2013; Selzer et al., 2013).
Tape-stripping technique
The tape-stripping technique is applied in vitro for 
analyses of drug penetration into the stratum corneum. The 
procedure may be applied in vivo using animal models or 
human volunteers, once that it is minimally invasive and 
painful. This technique has also been applied to assess the 
potential toxicity of bioactive compounds absorbed by the 
stratum corneum (Klang et al., 2012; Selzer et al., 2013; 
Paleco et al., 2014). 
The tape-stripping technique involves sequential 
removal of cell layers of the stratum corneum by 
application of pieces of adhesive tape. The residues of 
the formulation are previously removed from the skin 
surface, and the tape is applied by using pressure to ensure 
its adhesion to the skin. When the tape is removed, a 
portion of the stratum corneum is also removed. The first 
piece of tape is discarded to eliminate the residues of the 
formulation. The other pieces of tape are sequentially 
applied (mean of 16 applications) to strip the skin on the 
site where the formulation was administered. The pressure 
and speed of application should be the same during the 
entire process to assure the homogeneity of the relative 
amount of stratum corneum removed. The pieces of the 
tape are collected, and drug extraction is performed by 
using solvents. The solvents are selected on the basis of the 
drug solubility. The samples are stirred and centrifuged, 
and the drug is recovered in the supernatant. Validation 
studies are performed by using spiked tapes with known 
drug concentrations for determination of the percentage of 
recovery. The dermatopharmacokinetic studies of the drug 
may be performed in vivo by tape-stripping to evaluate 
the bioavailability of drugs from topical formulations 
(hydrogels, creams, and ointments) (Nair et al., 1997; 
Moser et al., 2001; Yamashita, Hashida, 2003; Anissimov 
et al., 2013; Selzer et al., 2013).
Matos et al. (2015) performed an interesting tape-
stripping procedure of the porcine ear skin after the 
administration of nanoparticles containing minoxidil, 
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TABLE I - Some experimental conditions used for evaluation of in vitro skin permeation of drugs
Drug (Log Pa) Skin model Receptor medium/Temperature/Stirring Diffusion cell type Studied time Reference
Testosterone 
(Log P = 3.47) Rat skin
Saline + 40% 
Polyethylene glycol 
400/37 °C/NIc
Keshary-Chien 26 h Kim et al., 2001
Oxybutynin 
(Log P = 5.19) Rabbit ear skin 0.9% Saline/37°C/NI
c Franz 8 h Nicoli et al., 2006
Valsartan 
(Log P = 4.75)
Rat and hairless 
mice skin, skin of 
Yucatan micropig 
(dermatomated)
PBSb pH 7.4/37°C/
600 rpm Vertical
8 h for drug 
suspensions, 
and 48 h for 
transdermal 
patches
Nishida et al., 2010
Ondansetron 
(Log P = 2.07) Hairless mice skin PBS
b pH 7.4/37°C/NIc Franz NIc Obata et al., 2010
Nicotine 
(Log P = 0.72)
Human skin 
(200 µm, 
dermatomated)
Saline 0.9%/37°C/NIc
Diffusion cell 
modified with 
silver–silver 
chloride electrode
NIb Wu et al., 2010
Theophylline 
(Log P = –0.17) and 
hydrocortisone 
(Log P = 1.43)
Porcine ear skin
PBSb pH 7.4 + 0.03% 
of sodium azide 
(preservative)/32°C/NIc
Franz
48 h 
(theophylline) 
and 52 h 
(hydrocortisone)
Novotný et al., 2011
Diclofenac sodium 
(Log P = 4.06)
Human skin (only 
epidermis)
PBSb pH 7.4 + 2.5% 
hydroxypropyl-β-
cyclodextrin/NIb/400 rpm
Franz NIb Snorradóttir et al., 2011
Donepezil 
(Log P = 4.71)
Hairless mice and 
human skin
PBSb pH 7.4/32°C/
600 rpm Keshary-Chien 12 h Choi et al., 2012
Timolol 
(Log P = 0.68)
Guinea pig skin and 
human skin
Phosphate buffer pH 
7.4/37 °C/600 rpm
Keshary-Chien 
modified with 
silver–silver 
chloride electrode
7h Patni et al., 2012
Donepezil 
(Log P = 4.71) Hairless mice skin Buffer pH 6.0/37°C/NI
c Flow-through cell 24 h Subedi et al., 2012
Theophylline 
(Log P = –0.17) and 
hydrocortisone 
(Log P = 1.43)
Porcine ear skin
PBSb pH 7.4 + 0.03% 
of sodium azide 
(preservative)/32°C/NIc
Franz
48 h 
(theophylline) 
and 52 h 
(hydrocortisone)
Janůšová et al., 2013
Fluoxetine 
(Log P = 4.09)
Hairless mice, rat 
and human skin
PBSb pH 7.4 + 6% of 
Brij98d/37 °C/600 rpm Keshary-Chien 12 h Jung et al., 2013
Nicotine 
(Log P = 0.72) Porcine ear skin
PBSb pH 7.4/32°C/
600 rpm Vertical 48 h
Ruela et al., 2013; 
Ruela, Figueiredo, 
Pereira, 2014
Isosorbide dinitrate 
(Log P = –0.90)
Hairless rat skin
Saline + 
Polyethyleneglycol 
400/37 °C/200 rpm
Franz 24 h Zhan et al., 2015
aACD/Log P values from www.chemspider.com (Royal Society of Chemistry); bPBS, phosphate-buffered saline; cNI, not 
informed; dBrij98, polyoxyethylene(20) oleyl ether.
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analyzing the retention of this drug in the stratum corneum 
and follicular casts. Analysis of the drug retained in the 
stratum corneum was performed by using the conventional 
tape-stripping technique, and analysis of the drug retained 
in the follicular casts was performed by application of 
cyanoacrylate glue to the stripped skin, which was covered 
with a tape strip. After the glue was polymerized by 
exposure to ultraviolet light, the tape strip was removed, 
and the drug in the follicular casts was recovered from the 
glue and analyzed by HPLC. Similar results of differential 
stripping combined with other techniques were previously 
obtained by Desai et al. (2013), which demonstrated that 
percutaneous permeation pathways (follicular or non-
follicular) may be studied after topical administration of 
drugs.
In general, some considerations must be taken 
before the tape-stripping procedure. The application site 
should be uniform and without skin damage. The adhesive 
tapes can be purchased from different manufacturers, but 
they must be compatible with the solvent used for drug 
extraction. The tapes with acrylic or silicone adhesives 
are widely used for this purpose. Moreover, the tape must 
be innocuous and does not cause allergic reactions or 
inflammation in the skin (Haag et al., 2011; Klang et al., 
2012).
Recent advances in the tape-stripping technique 
were achieved by its combination with other techniques, 
such as attenuated total reflectance Fourier-transform 
infrared (ATR-FTIR) and confocal laser scanning 
microscopy. These approaches will be discussed in the 
following sections.
Studies of cutaneous retention
Cutaneous retention of drugs and other bioactive 
compounds can be assessed by direct measurements of 
drug concentration in the whole skin and skin layers 
previously isolated or by using reconstructed skin 
models. The skin layers can be isolated by using several 
techniques. The dermis and epidermis are separated by 
immersing the skin in heated water (60 °C) for 1 minute. 
Next, the epidermis is detached from the dermis. The 
stratum corneum also can be isolated by immersing the 
whole skin in a trypsin solution at 37 °C for 24 h. After 
digestion of the skin by an enzymatic solution, only the 
stratum corneum is recovered (Snorradóttir et al., 2011; 
Mcauley et al., 2013; Wang et al., 2014).
Experimental protocols are based on in vitro and in 
vivo evaluations of skin penetration. These evaluations 
may be performed in vitro after the skin permeation assays 
using diffusion cells (Reid et al., 2013, Ruela et al., 2013; 
Paleco et al., 2014; Shah et al., 2015). Animal models 
(mice or rats) have been employed for in vivo evaluations. 
These evaluations must be based on protocols previously 
approved by an ethics committee. In these cases, the 
formulations are administered to the skin of the animal, 
and after a predetermined time interval, the animals 
are euthanized and the site of application is surgically 
removed for analysis of drug retained in the skin (Lopes 
et al., 2006; Vicentini et al., 2008). For drug analysis, 
the skin is cut into small pieces that are vortexed in a 
solvent for drug extraction. The skin tissue may also be 
homogenized by using an Ultra-Turrax type homogenizer. 
Drug quantification is performed by using selective and 
validated analytical methods. In general, HPLC is the 
analytical technique usually employed (Ruela et al., 2013).
Presently, there is a trend in replacement methods 
for animal experimentation, and 3D in vitro reconstructed 
human skin models are alternatives to animal testing (Gotz 
et al., 2012; Dos Santos et al., 2015). Three-dimensional 
(3D) in vitro skin models have been employed in both 
academic and research laboratories of skin-related 
industries to evaluate the toxicity and efficacy of drugs, 
drug products, and cosmetics and to study interactions 
between skin and its microbiome (Bojar, 2015; Dos 
Santos et al., 2015). Commercial skin substitutes based on 
keratinocytes and human fibroblasts are available and are 
recommended for testing skin irritation and skin corrosion 
(Groeber et al., 2011). Despite the significant value of 
these skin models for screening drugs and drug products, 
there are some limitations of 3D in vitro skin models 
because they cannot provide a more complex environment 
of the full thickness of the normal adult skin. 3D in vitro 
skin models are usually reconstructed from primary adult 
human fibroblast and keratinocytes, without incorporation 
of melanocytes and Langerhans’s cells, which require 
complex nutritional and physical requirements for each 
cell type (Groeber et al., 2011; Gotz et al., 2012; Bojar, 
2015; Dos Santos et al., 2015). In vitro skin substitutes 
have not yet achieved appreciable application in 
evaluations of drug skin permeation. However, tissue 
engineering has shown potential for the development of 
more complex 3D in vitro skin models to substitute excised 
skin from animals, including disease skin models, such 
as psoriasis, and in vitro infection models, such as herpes 
models, papilloma viruses, and Candida albicans (Groeber 
et al., 2011; Bojar, 2015).
In vivo evaluation of the skin permeation of drugs
Evaluation of in vivo skin absorption is performed 
by conducting pharmacokinetic studies or alternatively 
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by using cutaneous microdialysis. In both cases, these 
evaluations have been performed with human volunteers 
or animal models and protocols previously approved by 
an ethics committee.
Preclinical pharmacokinetic evaluations
Preclinical pharmacokinetic evaluations with animal 
models precede clinical trials with human volunteers. 
The aim of these investigations is to determine if the 
target plasma concentrations of the drug are achieved 
or sustained for prolonged periods after administration 
of the transdermal formulation. In many cases, in 
vivo–vitro correlations are determined from the in vitro 
skin permeation data (Lin, Ho, Chien, 1993; Wilding et 
al., 1996; Costa, Sousa Lobo, 2001; Zhao et al., 2006; 
Farahmand, Maibach, 2009; Ren et al., 2009).
In general, the pharmacokinetic evaluations 
use plasma concentrations of the drug. For this, 
blood samples are collected at different times after 
administration of the transdermal delivery system. 
Plasma is separated immediately by centrifugation, and 
the drug is extracted and analyzed by using a selective 
analytical method, such as HPLC or gas chromatography. 
In many cases, the use of chromatographic techniques 
coupled with mass spectrometry is necessary. The 
pharmacokinetic parameters are determined from a 
plot of drug plasma concentrations versus time. The 
recommended parameters to be calculated are the area 
under the curve, the peak plasma concentration of the 
drug, and the time needed to reach the maximum. Drug 
concentration in the steady state and the lag time may 
be also determined. Rat models are generally used in 
these studies (hairless, Wistar, or Sprague–Dawley). The 
transdermal formulation is administered in the dorsal 
or abdominal regions of the animals (Kim et al., 2001; 
Nishida et al., 2010; Yang et al., 2012; Jung et al., 2013). 
Beagle dogs and guinea pigs are selected in some studies 
(Ye et al., 2008; Chen et al., 2013). Although these 
preclinical evaluations are important, the results cannot 
be extrapolated to humans if the selected animal models 
show significant differences in skin permeability, drug 
metabolism, and elimination (Choi et al., 2012; Jung et 
al., 2013).
Hair removal at the site of application may be 
necessary before the administration of transdermal 
formulations in animal models and can be done by 
using a clipper or depilatory creams (Gupta et al., 1993; 
Nishida et al., 2010; Choi et al., 2012; Saluja et al., 2013). 
The integrity of the skin permeability must be assured. 
Transepidermal water loss from the skin or electrical 
conductivity measurements across the skin are useful for 
detection of skin damage, physical injury, or pathological 
conditions. The toxicity of the drug or formulation in 
the skin also may be investigated (Ashtikar et al., 2013; 
Pažoureková et al., 2013; Oliveira et al., 2014; Guth et 
al., 2015).
Pharmacokinetic evaluations of a transdermal 
delivery system are essential to determine the in vivo 
behavior of the drug administered by the skin route 
because in vitro studies cannot reproduce the complexity 
of biological systems, such as metabolism, distribution, 
and elimination. The contribution of skin absorption 
by different pathways, such as the epidermis or skin 
appendages, is also important and may be characterized 
during the preclinical pharmacokinetic studies (Godin, 
Touitou, 2007; Farahmand, Maibach, 2009).
Cutaneous microdialysis
In vivo evaluations using cutaneous microdialysis 
have  been used for  quant i f ica t ion  of  cerebra l 
neurotransmitters (Shearman et al., 2006; Cerbai et 
al., 2007; Shannon et al., 2013), glucose monitoring 
in diabetes mellitus (Mader et al., 2012), measurement 
of antibiotics levels (Roberts et al., 2008; K. Hurtado 
et al., 2014), and measurement of antineoplastic drug 
levels in the target tissue (Höcht, Opezzo, Taira, 2007). 
Among these applications, the assessment of in vivo 
skin absorption of drugs from topical and transdermal 
formulations has also been described (Schnetz, Fartasch, 
2001; Kreilgaard, 2002; Brunner, Derendorf, 2006). 
Although the traditional pharmacokinetic evaluations 
assess the total drug in the sample (drug–protein binding 
and free drug fraction), this technique measures only the 
free drug fraction directly in the target tissue (Nakashima 
et al., 2006; Shearman et al., 2006; Zhang et al., 2007; 
Shinkai et al., 2011).
Cutaneous microdialysis is classified as a semi-
invasive technique in which a semipermeable microdialysis 
probe is inserted into defined skin layers (epidermis or 
dermis), directly under the formulation (Figure 3). The 
physiological solution (saline or Ringer’s solution) is 
slowly perfused by using a pump (1–10 µL/min). The 
compounds in the tissue interstitial fluid diffuse into the 
dialysate in the probe. The samples are free of proteins and 
other macromolecules because of the molecular weight 
cutoff of the semipermeable membranes (20-100 kDa). 
The dialysate is collected at different times, and the drug 
is directly analyzed by for example, HPLC. However, in 
some cases, because of the small amounts of sample (a 
few microliters) and the drug dilution, high sensitivity 
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analytical techniques, such as HPLC coupled with mass 
spectrometry, are required (Kreilgaard, 2002; Tang et al., 
2013).
The recovery of drug from the dialysate is an 
important parameter to be determined. The relative 
recovery of the drug is evaluated by using the retrodialysis 
technique. For these evaluations, a drug solution with 
known concentration is perfused for a defined time. Next, 
the drug concentration in the dialysate is determined 
(Kreilgaard, 2002; Brunner, Derendorf, 2006; Shinkai et 
al., 2011). The initial (Cinitial) and final (Cfinal) concentrations 
are used in the determination of the relative recovery 
according to the Equation (1):
  (1)
Cutaneous microdialysis shows better results for 
recovery of hydrophilic compounds, and some limitations 
have been reported for evaluation of lipophilic drugs. 
Once the dialysate is an aqueous solution, the recovery 
of lipophilic and poorly water-soluble drugs is very 
low. Compounds with high molecular weights, such as 
peptides and proteins, cannot be determined by cutaneous 
microdialysis because of the molecular weight cutoff of the 
membranes. Overall, the technique is attractive because 
of its relatively low cost relative to the costs of traditional 
pharmacokinetic studies (Kreilgaard, 2002; Brunner, 
Derendorf, 2006).
It also has been reported that cutaneous microdialysis 
offer advantages in relationship to in vivo tape-stripping 
for assessment of the bioavailability of drugs from topical 
formulations (Seki et al., 2004). Although tape-stripping 
only evaluates drug absorption in the stratum corneum, 
cutaneous microdialysis evaluates drug absorption in 
the depth layers of the skin. In these cases, cutaneous 
microdialysis enables characterization of skin absorption 
and clearance of drugs from topical formulations (Shinkai 
et al., 2011; Tang et al., 2013).
Leveque et al. (2004) studied the skin absorption 
of salicylic acid by using cutaneous microdialysis 
and compared the results with those from in vitro skin 
permeation studies using a Franz diffusion cell (Leveque 
et al., 2004). Even though the major salicylic acid levels 
were determined by using the microdialysis technique, the 
results showed good correlation.
Bioequivalence studies of topical formulations may 
be performed by using cutaneous microdialysis. Tettey-
Amlalo et al. (2009) evaluated the bioequivalence of 
ketoprofen gels by using this technique, and the results 
were compared with those of three different commercial 
products with satisfactory results (Tettey-Amlalo et al., 
2009).
Microscopic and spectroscopic methods applied 
to the percutaneous absorption of drugs
Recent advances in the evaluation of percutaneous 
absorption of drugs were achieved by using microscopic 
and spectroscopic methods. These new trends in skin 
absorption studies will be discussed in the following 
sections.
Attenuated total reflectance fourier-transform 
infrared spectroscopy
Attenuated Total Reflectance Fourier-Transform 
Infrared Spectroscopy (ATR-FTIR) has been applied 
to studies of the stratum corneum. These studies 
evaluated modifications in the permeability of the 
horny layer by using physical methods, treatment with 
chemical enhancers, examining the array of lipids and 
the conformation of proteins in the outermost layer of 
the skin. The displacement of the infrared bands of the 
FIGURE 3 - Cutaneous microdialysis.
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treated skin relative to those of the untreated skin helped to 
elucidate the modifications in the stratum corneum caused 
by chemical or physical treatments (Gupta, Jain, Varshney, 
2005; Gannu et al., 2007; Mcauley et al., 2013).
Skin samples are directly placed in a crystal of 
zinc selenite (ZnSe) without previous treatments (Moser 
et al., 2001). The bands in the range of 2930–2920 cm-1 
and 2855–2850 cm-1 are related to asymmetric and 
symmetric CH2 stretching that represents the lipid array 
in the stratum corneum. The lipid matrix of the horny 
layer has a liquid-crystalline array, and its hexagonal or 
orthorhombic conformation is related to the frequency of 
CH2 stretching. The hexagonal array is more fluid than 
is the orthorhombic one, which indicates increased skin 
permeability. Complementary information is obtained 
from angular deformation, such as scissoring of the CH 
bond (1454–1466 cm-1). When the hexagonal array is 
prevalent, just one band of CH scissoring is visualized; 
however, when the orthorhombic conformation is 
prevalent, two bands related to CH are observed in the 
same spectral region. The proteins of the stratum corneum 
also can be characterized by ATR-FTIR. The bands in the 
1640–1540 cm-1 range are related to the amine I and II 
of keratin, and the protein conformation is characterized 
as a random coil, α-helices, or a β-sheet. Rupture of the 
secondary structure of proteins (α or β) leads to the random 
coil conformation, which increases the skin permeability. 
The α-helices conformation (bands in higher frequencies) 
forms an array more densely packed than the β-sheet 
conformation. In this way, the prevalence of the α-helices 
conformation is indicative of a state of decreased skin 
permeability (Bernard et al., 2007; Schwarz, Pagitsch, 
Valenta, 2013; Balázs et al., 2014).
McAuley et al. (2013) studied the effect of fatty 
acids as chemical enhancers by ATR-FTIR (Mcauley 
et al., 2013). Cyanophenol was employed as a model 
molecule because this compound is easily identified in the 
infrared spectrum by its CN stretching at 2227 cm-1. The 
authors studied isolated skin layers (epidermis and stratum 
corneum) and used ATR-FTIR to characterize the Fickian 
diffusion of the molecule through the skin.
Wang et al. (2014) studied the effect of polymers 
based on β-cyclodextrins as chemical enhancers for 
transdermal therapy (Wang et al., 2014). ATR-FTIR 
studies using stratum corneum from mice skin tissues 
were performed. The effect of the polymers as chemical 
enhancers was related to modification of the secondary 
conformation of keratin in the horny layer. Schwarz et 
al. (2013) performed comparative studies of mucosal 
membranes (buccal and vaginal) and ear porcine skin 
by using ATR-FTIR (Schwarz, Pagitsch, Valenta, 2013). 
The array of lipids and proteins in the stratum corneum 
of different tissues was characterized along with the 
effect of the vehicle (lecithin-based microemulsion) 
on the skin permeability of flufenamic acid. In this 
case, the vehicle was prepared by using a deuterated 
component because the asymmetric and symmetric CD2 
stretching were observed in the 2195-2089 cm-1 range, 
without spectral interference of the skin. The authors 
employed deuterated phospholipids, and the ATR-FTIR 
results were compared with those obtained by using the 
tape-stripping technique. The determination of drug 
concentrations in the skin layers by using ATR-FTIR did 
not show satisfactory results because of the attenuation 
of the infrared signal that depended on the depth in 
the skin. Under these conditions, the authors observed 
that the Lambert–Beer law did not show its typical 
proportionality to drug concentration.
Confocal laser scanning microscopy
Confocal laser scanning microscopy (CLSM) is 
a non-invasive technique derived from fluorescence 
microscopy. Presently, CLSM is a well-established 
technique for obtaining high-resolution images with 
depth selectivity. CLSM has been applied in vivo and in 
vitro to study the skin structure without physically cutting 
tissue as well as to assess the effects of physical and 
chemical enhancers on skin permeability. CLSM is 
also used to diagnose common benign skin lesions 
and to characterize malignant lesions. Applications of 
CLSM include the characterization of keratinization and 
pigmentation disorders (Caspers et al., 2001; Ashtikar et 
al., 2013; Franzen, Anderski, Windbergs, 2015).
Fluorescent markers, such as fluorescein, Nile red, 
and 5-bromodeoxyuridine, penetrate the skin, and their 
skin localization can be characterized by CLSM. These 
compounds may be incorporated in nanostructured drug 
delivery systems in which they are encapsulated. The effect 
of these drug delivery systems can be studied by CLSM to 
characterize the permeation profiles of these fluorescent 
markers across the skin or skin appendages. CLSM is 
based on a laser source that emits a monochromatic beam 
to excite the fluorescent markers. The fluorescence emitted 
by the specimen in a single plane is filtered through a 
dichroic mirror to reach the objective lens, which gives 
a high-resolution image. The main advantage of CLSM 
is that it enables characterization of the skin in depth 
at different focal planes. Thus, the images generated at 
different planes are combined to obtain a 3D image of the 
sample (Caspers et al., 1998; Pereira et al., 2002; Das, 
Agrawal, 2011; Mateus et al., 2013).
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Some limitations of CLSM have been reported 
and include the limited number of fluorescent markers 
available for these studies and that only semi-quantitative 
assessments based on fluorescence signals can be 
performed. The images are also limited to determined 
points of the skin at determined times, and the images do 
not represent the dynamic process of skin permeation for 
prolonged times (Darlenski et al., 2009; Franzen et al., 
2013; Franzen, Anderski, Windbergs, 2015).
Raman confocal microscopy
Raman spectroscopy is a technique analogous 
to ATR-FTIR, but it does not suffer from interference 
by water. Infrared spectroscopy is based on absorption 
of light, but Raman spectroscopy is based on inelastic 
scattering of monochromatic light from a laser beam. From 
the inelastic scattering, the alterations in the wavelength 
of the photons, which provide a fingerprint by which 
molecules can be identified in the sample, are analyzed. 
The excitation or deactivation of molecular vibrations is 
related to the energetic variations in the photons. Thus, it is 
possible to obtain detailed information about the chemical 
structure, electronic configuration, and molecular bonds 
of a compound. Raman spectroscopy has been applied in 
different fields as pathology, cosmetics, and pharmaceutical 
sciences (Caspers et al., 2001; Darlenski et al., 2009).
The association of CLSM and Raman spectroscopy 
in the last two decades has contributed to the recent 
advances in the study of skin barrier properties (Caspers 
et al., 1998; Caspers et al., 2001). This association has 
led to the development of Raman confocal microscopy 
(RCM), a non-invasive technique that has the combined 
advantages of Raman spectroscopy and CLSM (Figure 4) 
(Baena, Lendl, 2004; Darlenski et al., 2009).
RCM has enabled study of the quali tat ive 
biochemical composition of the skin regarding the lipids 
in the stratum corneum and of natural moisturizing factor 
components. The thickness of the horny layer and its water 
concentration also has been determined by RCM. Recent 
studies using RCM have been conducted to determine 
the skin absorption of drugs. These studies are limited by 
signal attenuation in the depth layers of the skin. In the 
same way as ATR-FTIR signals, refraction index values 
are altered in the depth layers, and the light scattering 
becomes more diffuse with increasing skin depth (Franzen 
et al., 2013).
Mateus et al. (2013) studied the dermato pharma-
cokinetics of ibuprofen in human volunteers by using 
RCM and compared the results with those obtained 
by using the tape-stripping technique (MATES et al., 
2013). In both cases, drug diffusion was characterized 
according to Fick’s law. When RCM was employed, 
relative measurements of drug concentrations in the skin 
layers were made and compared with the initial amount 
of drug on the skin surface. This procedure did not allow 
the precise determination of the drug concentrations in 
each skin layer.
Franzen et al.  (2013) studied mathematical 
algorithms for correction of the signal attenuation at 
different skin layers for quantitative analysis of the 
skin penetration of caffeine (Franzen et al., 2013). For 
this, the authors created a simulated matrix of keratin, 
water, and various lipids to obtain a sample with optical 
properties similar to those of the stratum corneum. The 
drug was incorporated in the simulated matrix at known 
concentrations, and the concentrations at different 
depths were quantitatively determined. The results were 
promising for quantitative determination of caffeine by 
using RCM. Recently, the validation of an in vitro method 
FIGURE 4 - Analysis using Raman confocal microscopy.
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by RCM for quantitative analysis of caffeine in skin was 
reported as an interesting non-invasive strategy for drug 
quantification directly in the skin by using a non-invasive 
technique (Franzen, Anderski, Windbergs, 2015).
CONCLUSIONS
Although there are different in vitro and in vivo 
methods for evaluation of the cutaneous absorption 
of drugs and bioactive molecules, pharmaceutical 
formulation scientists must select those best suited to 
their investigations. Thus, the success of topical and 
transdermal administration of drugs is directly related 
to the methods used for evaluation of the formulations, 
which enable optimization of the skin absorption of the 
drug so that it can reach effective drug concentrations at 
the therapeutic site.
ACKNOWLEDGMENTS
The authors are grateful for CAPES (Brasília, 
Brazil), CNPq (Brasília, Brazil), and Unifal-MG (Alfenas, 
Brazil) for research fellowships.
REFERENCES
ANDREWS, S.N.; JEONG, E.; PRAUSNITZ, M.R. Transdermal 
delivery of molecules is limited by full epidermis, not just 
stratum corneum. Pharm. Res., v.30, n.4, p.1099-109, 2013.
ALEXANDER, A.; DWIVEDI, S.; AJAZUDDIN; GIRI, T.K.; 
SARAF, S.; SARAF, S.; TRIPATHI, D.K. Approaches 
for breaking the barriers of drug permeation through 
transdermal drug delivery. J. Control. Rel., v.164, n.1, 
p.26-40, 2012.
ANISSIMOV, Y.G.; JEPPS, O.G.; DANCIK, Y.; ROBERTS, 
M.S. Mathematical and pharmacokinetic modelling of 
epidermal and dermal transport processes. Adv. Drug Deliv. 
Rev., v.65, n.2, p.169-190, 2013.
ASHTIKAR, M.; MATTHÄUS, C.; SCHMITT, M.; KRAFFT, 
C.; FAHR, A.; POPP, J. Non-invasive depth profile imaging 
of the stratum corneum using confocal Raman microscopy: 
First insights into the method. Eur. J. Pharm. Sci., v.50, n.5, 
p.601-608, 2013.
AZARMI, S.; ROA, W.; LÖBENBERG, R. Current perspectives 
in dissolution testing of conventional and novel dosage 
forms. Int. J. Pharm., v.328, n.1, p.12-21, 2007. 
BAENA, J.R.; LENDL, B. Raman spectroscopy in chemical 
bioanalysis. Curr. Opin. Chem. Biol., v.8, n.5, p.534-539, 
2004. 
BALÁZS, B.; FARKAS, G.; BERKESI, O.; GYULAI, R.; 
BERKÓ, S.; BUDAI-SZŰCS, M.; SZABÓ-RÉVÉSZ, P.; 
KEMÉNY, L.; CSÁNYI, E. Protein structure is changed in 
psoriatic skin on the unaffected region - Imaging possibility 
with ATR-FTIR spectroscopy. Microchem. J., v.117, p.183-
186, 2014.
BARRY, B.W. Novel mechanisms and devices to enable 
successful transdermal drug delivery. Eur. J. Pharm. Sci., 
v.14, n.2, p.101-114, 2001. 
BERNARD, G.; AUGER, M.; SOUCY, J.; POULIOT, R. 
Physical characterization of the stratum corneum of an 
in vitro psoriatic skin model by ATR-FTIR and Raman 
spectroscopies. Biochim. Biophys. Acta, v.1770, n.9, 
p.1317-1323, 2007. 
BOJAR, R.A. Studying the human skin microbiome using 3D 
in vitro skin models. Applied In Vitro Toxicol., v.1, n.2, 
p.165-71, 2015.
BROWN, C.K.;  CHOKSHI, H.P.;  NICKERSON, B.; 
REED, R.A; ROHRS, B.R.; SHAH, P.A. Acceptable 
analytical practices for dissolution testing of poorly soluble 
compounds. Pharm. Technol., v.28, n.12, p.56, 2004. 
BRUNNER, M.; DERENDORF, H. Clinical microdialysis: 
Current applications and potential use in drug development. 
TrAC Trends in Anal. Chem., v.25, n.7, p.674-680, 2006.
CARDOT, J.; BEYSSAC, E.; ALRIC, M. In vitro-in vivo 
correlation: Importance of dissolution in IVIVC. Dissol. 
Technol., p.15-19, 2007.
CASPERS, P.J.;  LUCASSEN, G.W.; CARTER, E.A; 
BRUINING, H.A; PUPPELS, G.J. In vivo confocal Raman 
microspectroscopy of the skin: Noninvasive determination 
of molecular concentration profiles. J. Invest. Dermatol., 
v.116, n.3, p.434-442, 2001.
CASPERS, P.J.; LUCASSEN, G.W.; WOLTHUIS, R.; 
BRUINING, H. A.; PUPPELS, G.J. In vitro and in vivo 
Raman spectroscopy of human skin. Biospectroscopy, v.4, 
n.5 Suppl, p.S31-S39, 1998. 
Evaluation of skin absorption of drugs from topical and transdermal formulations 539
CERBAI, F.; GIOVANNINI, M.G.; MELANI, C.; ENZ, 
A.; PEPEU, G. N1phenethyl-norcymserine, a selective 
butyrylcholinesterase inhibitor, increases acetylcholine 
Release in rat cerebral cortex: A comparison with donepezil 
and rivastigmine. Eur. J. Pharmacol., v.572, n.2-3, p.142-
50, 2007.
CEVC, G.; VIERL, U. Nanotechnology and the transdermal 
route. A state of the art review and critical appraisal. J. 
Control. Release, v.141, n.3, p.277-299, 2010. 
CHEN, J.; HU, W.; QU, Y.Q.; DONG, J.; GU, W.; GAO, Y.; 
FANG, Y.; FANG, F.; CHEN, Z.P.; CAI, B.C. Evaluation 
of the pharmacodynamics and pharmacokinetics of brucine 
following transdermal administration. Fitoterapia, v.86, 
n.1, p.193-201, 2013.
CHEN, L.; HAN, L.; LIAN, G. Recent advances in predicting 
skin permeability of hydrophilic solutes. Adv. Drug Deliv. 
Rev., v.65, n.2, p.295-305, 2013.
CHOI, J.; CHOI, M.-K.; CHONG, S.; CHUNG, S.-J.; SHIM, 
C.-K.; KIM, D.-D. Effect of fatty acids on the transdermal 
delivery of donepezil: In vitro and in vivo evaluation. Int. 
J. Pharm., v.422, n.1-2, p.83-90, 2012.
COSTA, P.; SOUSA LOBO, J.M. Modeling and comparison of 
dissolution profiles. Eur. J. Pharm. Sci., v.13, n.2, p.123-
133, 2001. 
DARLENSKI, R.; SASSNING, S.; TSANKOV, N.; FLUHR, 
J. W. Non-invasive in vivo methods for investigation of the 
skin barrier physical properties. Eur. J. Pharm. Biopharm., 
v.72, n.2, p.295-303, 2009.
DAS, R.S.; AGRAWAL, Y.K. Raman spectroscopy: Recent 
advancements, techniques and applications. Vib. Spectrosc., 
v.57, n.2, p.163-176, 2011.
DELGADO-CHARRO, M.B.; GUY, R.H. Effective use of 
transdermal drug delivery in children. Adv. Drug Deliv. 
Rev., v.73, p.63-82, 2014.
DESAI, P.R.; SHAH, P.P.; HAYDEN, P.; SINGH, M. 
Investigation of follicular and non-follicular pathways for 
polyarginine and oleic acid modified nanoparticles. Pharm. 
Res., v.30, n.4, p.1037-49, 2013.
DOS SANTOS, M.; METRAL, E.; BOHER, A.; ROUSSELLE, 
P.; THEPOT, A.; DAMOUR, O. In vitro 3-Dmodel based 
on extending time of culture for studying chronological 
epidermis aging. Matrix Biol., v.47, p.85-97, 2015.
EL MAGHRABY, G.M.; BARRY, B.W.; WILLIAMS, 
A.C. Liposomes and skin: From drug delivery to model 
membranes. Eur. J. Pharm. Sci., v.34, n.4-5, p.203-222, 
2008. 
FARAHMAND, S.; MAIBACH, H.I. Transdermal drug 
pharmacokinetics in man: Interindividual variability and 
partial prediction. Int. J. Pharm., v.367, n.1-2, p.1-15, 2009. 
FOUAD, S.A.; BASALIOUS, E.B.; EL-NABARAWI, 
M.A.; TAYEL, S.A. Microemulsion and poloxamer 
microemulsion-based gel for sustained transdermal delivery 
of diclofenac epolamine using in-skin drug depot: In vitro/in 
vivo evaluation. Int. J. Pharm., v.453, n.2, p.569-578, 2013. 
FRANZEN, L.; ANDERSKI, J.; WINDBERGS, M. Quantitative 
detection of caffeine in human skin by confocal Raman 
spectroscopy - A systematic in vitro validation study. Eur. 
J. Pharm. Biopharm., v.95, pt.A, p. 110-116, 2015.
FRANZEN, L.; SELZER, D.; FLUHR, J.W.; SCHAEFER, U.F.; 
WINDBERGS, M. Towards drug quantification in human 
skin with confocal Raman microscopy. Eur. J. Pharm. 
Biopharm., v.84, n.2, p.437-444, 2013.
FRASCH, H.F.; BARBERO, A.M. Application of numerical 
methods for diffusion-based modeling of skin permeation. 
Adv. Drug Deliv. Rev.,v.65, n.2, p.208-220, 2013. 
FRUM, Y.;  KHAN, G.M.;  SEFCIK,  J . ;  ROUSE, J . ; 
ECCLESTON, G.M.; MEIDAN, V.M. Towards a 
correlation between drug properties and in vitro transdermal 
flux variability. Int. J. Pharm., v.336, n.1, p.140-147, 2007. 
GANNU, R.; VISHNU, Y.V.; KISHAN, V.; RAO, Y.M. 
Development of nitrendipine transdermal patches: In vitro 
and ex vivo characterization. Curr. Drug Deliv., v.4, n.1, 
p.69-76, 2007. 
GODIN, B.; TOUITOU, E. Transdermal skin delivery: 
Predictions for humans from in vivo, ex vivo and animal 
models. Adv. Drug Deliv. Rev., v.59, n.11, p.1152-1161, 
2007. 
A. L. M. Ruela, A. G. Perissinato, M. E. S. Lino, P. S. Mudrik, G. R. Pereira540
GOTZ, C.; PFEIFFER, R.; TIGGES, J.; BLATZ, V.; JACKH, 
C.; FREYTAG, E.; FABIAN, E.; LANDSIEDEL, R.; 
MERK, H.F.; KRUTMANN, J.; EDWARDS, R.J.; 
PEASE, C.; GOEBEL, C.; HEWITT, N.; FRITSCHE, 
E. Xenobiotic metabolism capacities of human skin in 
comparison with a 3D epidermis model and keratinocyte-
based cell culture as in vitro alternatives for chemical 
testing: activating enzymes (Phase I). Exp. Dermatol., v.21, 
n.5, p.364-9, 2012.
GRATIERI, T.; KALIA, Y.N. Mathematical models to describe 
iontophoretic transport in vitro and in vivo and the effect 
of current application on the skin barrier. Adv. Drug Deliv. 
Rev., v.65, n.2, p.315-329, 2013. 
GRATIERI, T.; GELFUSO, G.M.; LOPEZ., R.V. F. Basic 
principles and aplications of iontophoresis for cutaneous 
penetration of drugs. Quim. Nova, v.31, n.6, p.1490-1498, 
2008. 
GROEBER, F.; HOLEITER, M.; HAMPEL, M.; HINDERER, 
S.; SCHENKE-LAYLAND, K. Skin tissue engineering - In 
vivo and in vitro applications. Adv. Drug Deliv. Rev., v.63, 
n.4, p.352-366, 2011.
GUPTA, R.R.; JAIN, S.K.; VARSHNEY, M. AOT Water-in-oil 
microemulsions as a penetration enhancer in transdermal 
drug delivery of 5-fluorouracil. Colloids Surf. B Biointerf., 
v.41, n.1, p.25-32, 2005. 
GUPTA, S.K.; BENOWITZ, N.L.; JACOB, P.; ROLF, C.N.; 
GORSLINE, J. Bioavailability and absorption kinetics of 
nicotine following application of a transdermal system. Br. 
J. Clin. Pharm., v.36, n.3, p.221-227, 1993. 
GUTH, K.; SCHÄFER-KORTING, M.; FABIAN, E.; 
LANDSIEDEL, R.; VAN RAVENZWAAY, B. Suitability 
of skin integrity tests for dermal absorption studies in vitro. 
Toxicol. In Vitro, v.29, n.1, p.113-123, 2015. 
HAAG, S.F.; FLEIGE, E.; CHEN, M.; FAHR, A.; TEUTLOFF, 
C.; BITTL, R.; LADEMANN, J.; SCHÄFER-KORTING, 
M.; HAAG, R.; MEINKE, M.C. Skin penetration 
enhancement of core-multishell nanotransporters and 
invasomes measured by electron paramagnetic resonance 
spectroscopy. Int. J. Pharm., v.416, n.1, p.223-228, 2011.
HANSON, R. A primer on release-rate testing of semisolids. 
Dissol. Technol., v.17, n.4, p.33-35, 2010. 
HEARD, C.M.; JOHNSON, S.; MOSS, G.; THOMAS, C.P. 
In vitro transdermal delivery of caffeine, theobromine, 
theophylline and catechin from extract of guarana, Paullinia 
Cupana. Int. J. Pharm., v.317, n.1, p.26-31, 2006. 
HÖCHT, C.; OPEZZO, J.A.W.; TAIRA, C.A. Applicability of 
reverse microdialysis in pharmacological and toxicological 
studies. J. Pharmacol. Toxicol. Meth., v.55, n.1, p.3-15, 
2007. 
JANŮŠOVÁ, B.;  ŠKOLOVÁ, B.;  TÜKÖROVÁ, K.; 
WOJNAROVÁ, L.; ŠIMŮNEK, T.; MLADĚNKA, 
P.; FILIPSKÝ, T.; ŘÍHA, M.; ROH, J.; PALÁT, K.; 
HRABÁLEK, A.; VÁVROVÁ, K. Amino acid derivatives 
as transdermal permeation enhancers. J. Control. Release, 
v.165, n.2, p.91-100, 2013. 
JEPPS, O.G.; DANCIK, Y.; ANISSIMOV, Y.G.; ROBERTS, 
M.S. Modeling the human skin barrier - Towards a better 
understanding of dermal absorption. Adv. Drug Deliv. Rev., 
v.65, n.2, p.152-158, 2013. 
JUNG, E.; KANG, Y.P.; YOON, I.S.; KIM, J.S.; KWON, S.W.; 
CHUNG, S.J.; SHIM, C.K.; KIM, D.D. Effect of permeation 
enhancers on transdermal delivery of fluoxetine: In vitro 
and in vivo evaluation. Int. J. Pharm., v.456, n.2, p.362-
369, 2013.
K. HURTADO, F.; LAUREANO, J.V.; DE A. LOCK, G.; 
DERENDORF, H.; DALLA COSTA, T. Enhanced 
penetration of moxifloxacin into rat prostate tissue 
evidenced by microdialysis. Int. J. Antimicrob. Agents, v.44, 
n.4, p.327-333, 2014. 
KALIA, Y.N.; GUY, R.H. Modeling transdermal drug release. 
Adv. Drug Deliv. Rev., v.48, n.2-3, p.159-172, 2001. 
KARADZOVSKA, D.; BROOKS, J.D.; MONTEIRO-
RIVIERE, N.A.; RIVIERE, J.E. Predicting skin permeability 
from complex vehicles. Adv. Drug Deliv. Rev., v.65, n.2, 
p.265-277, 2013.
KIM, M.K.; ZHAO, H.; LEE, C.H.; KIM, D.D. Formulation of 
a reservoir-type testosterone transdermal delivery system. 
Int. J. Pharm., v.219, n.1-2, p.51-59, 2001. 
KLANG, V.; SCHWARZ, J.C.; LENOBEL, B.; NADJ, M.; 
AUBÖCK, J.; WOLZT, M.; VALENTA, C. In vitro vs. in 
vivo tape stripping: Validation of the porcine ear model and 
penetration assessment of novel sucrose stearate emulsions. 
Eur. J. Pharm. Biopharm., v.80, n.3, p.604-614, 2012.
Evaluation of skin absorption of drugs from topical and transdermal formulations 541
KREILGAARD, M. Assessment of cutaneous drug delivery 
using microdialysis. Adv. Drug Deliv. Rev., v.54 Suppl 1, 
p.S99-121, 2002.
LEVEQUE, N.; MAKKI, S.; HADGRAFT, J.; HUMBERT, P. 
Comparison of Franz cells and microdialysis for assessing 
salicylic acid penetration through human skin. Int. J. 
Pharm., v.269, n.2, p.323-328, 2004.
LEWIS, D.; PAULO, M.; FAUSTINO, E. In vitro comparative 
studies of transdermal nicotine delivery systems. Int. J. 
Pharm., v.148, n.2, p.177-189, 1997. 
LIN, S.; HO, H.; CHIEN, Y.W. Development of a new nicotine 
transdermal delivery system: In vitro kinetics studies and 
clinical pharmacokinetic evaluations in two ethnic groups. 
J. Control. Release, v.26, n.3, p.175-193, 1993. 
LIU, N.; ZHANG, Y.; CUN, D.; QUAN, P.; FANG, L. Effect of 
Backing Films on the Transdermal Delivery of Conepezil 
from Patches. AAPS Pharm. Sci. Tech., v.15, p.1569-1573, 
2014.
LOPES, L.B.; FERREIRA, D.A.; DE PAULA, D.; GARCIA, 
M.T.J.; THOMAZINI, J.A.; FANTINI, M.C.A; BENTLEY, 
M.V.L.B. Reverse hexagonal phase nanodispersion of 
monoolein and oleic acid for topical delivery of peptides: In 
vitro and in vivo skin penetration of cyclosporin A. Pharm. 
Res., v.23, n.6, p.1332-1342, 2006. 
MADER, J.K.; FEICHTNER, F.; BOCK, G.; KÖHLER, G.; 
SCHALLER, R.; PLANK, J.; PIEBER, T.R.; ELLMERER, 
M. Microdialysis-A versatile technology to perform 
metabolic monitoring in diabetes and critically ill patients. 
Diabetes Res. Clin. Pract., v.97, n.1, p.112-118, 2012.
MANADAS, R.; PINA, M. E.; VEIGA, F. A dissolução in 
vitro na previsão da absorção oral de fármacos em formas 
farmacêuticas de liberação modificada. Rev. Bras. Ciênc. 
Farm., v.38, n.4, 2002. 
MATEUS, R.; ABDALGHAFOR, H.; OLIVEIRA, G.; 
HADGRAFT, J.; LANE, M.E. A New Paradigm in 
dermatopharmacokinetics - Confocal Raman spectroscopy. 
Int. J. Pharm., v.444, n.1-2, p.106-8, 2013. 
MATHES, S.H.; RUFFNER, H.; GRAF-HAUSNER, U. The 
use of skin models in drug development. Adv. Drug Deliv. 
Rev., v.69-70, p.81-102, 2014.
MATOS, B.N.; REIS, T.A.; GRATIERI, T.; GELFUSO, 
G.M. Chitosan nanoparticles for targeting and sustaining 
minoxidil sulphate delivery to hair follicles. Int. J. Biol. 
Macromol., v.75, p.225-9, 2015.
MCAULEY, W.J.; CHAVDA-SITARAM, S.; MADER, K.T.; 
TETTEH, J.; LANE, M.E.; HADGRAFT, J. The effects of 
esterified solvents on the diffusion of a model compound 
across human skin: An ATR-FTIR spectroscopic study. Int. 
J. Pharm., v.447, n.1-2, p.1-6, 2013.
MOSER, K.; KRIWET, K.; NAIK, A.; KALIA, Y.N.; GUY, R.H. 
Passive skin penetration enhancement and its quantification 
in vitro. Eur. J. Pharm. Biopharm., v.52, n.2, p.103-112, 
2001. 
NAEGEL, A.; HEISIG, M.; WITTUM, G. Detailed modeling of 
skin penetration- An overview. Adv. Drug Deliv. Rev., v.65, 
n.2, p.191-207, 2013.
NAIR, A.; JACOB, S.; AL-DHUBIAB, B.; ATTIMARAD, M.; 
HARSHA, S. Basic considerations in the dermatokinetics 
of topical formulations. Braz. J. Pharm. Sci., v.49, n.3, 
p.423-434, 2013. 
NAIR, M.K.; CHETTY, D.J.;  HO, H.;  CHIEN, Y.W. 
Biomembrane permeation of nicotine: Mechanistic studies 
with porcine mucosae and skin. J. Pharm. Sci., v.86, n.2, 
p.257-262, 1997.
NAKASHIMA, K.; ITOH, K.; KONO, M.; NAKASHIMA, 
M.N.; WADA, M. Determination of donepezil hydrochloride 
in human and rat plasma, blood and brain microdialysates 
by HPLC with a short C30 column. J. Pharm. Biom. Anal., 
v.41, n.1, p.201-206, 2006.
NICOLI, S.; PENNA, E.; PADULA, C.; COLOMBO, P.; 
SANTI, P. New transdermal bioadhesive film containing 
oxybutynin: In vitro permeation across rabbit ear skin. Int. 
J. Pharm., v.325, n.1-2, p.2-7, 2006. 
NISHIDA, N.; TANIYAMA, K.; SAWABE, T.; MANOME, 
Y. Development and evaluation of a monolithic drug-in-
adhesive patch for valsartan. Int. J. Pharm., v.402, n.1-2, 
p.103-109, 2010.
NOTMAN, R.; ANWAR, J. Breaching the skin barrier - Insights 
from molecular simulation of model membranes. Adv. Drug 
Deliv. Rev., v.65, n.2, p.237-250, 2013.
A. L. M. Ruela, A. G. Perissinato, M. E. S. Lino, P. S. Mudrik, G. R. Pereira542
NOVOTNÝ, M.; KLIMENTOVÁ, J.; JANŮŠOVÁ, B.; 
PALÁT, K.; HRABÁLEK, A.; VÁVROVÁ, K. Ammonium 
carbamates as highly active transdermal permeation 
enhancers with a dual mechanism of action. J. Control. 
Release, v.150, n.2, p.164-170, 2011. 
OBATA, Y.; ASHITAKA, Y.; KIKUCHI, S.; ISOWA, K.; 
TAKAYAMA, K.A Statistical approach to the development 
of a transdermal delivery system for ondansetron. Int. J. 
Pharm., v.399, n.1-2, p.87-93, 2010.
OLIVEIRA, G.; LEVERETT, J.C.; EMAMZADEH, M.; LANE, 
M.E. The effects of heat on skin barrier function and in vivo 
dermal absorption. Int. J. Pharm., v.464, n.1-2, p.145-151, 
2014.
PALECO, R.; VUČEN, S.R.; CREAN, A.M.; MOORE, A.; 
SCALIA, S. Enhancement of the in vitro penetration of 
quercetin through pig skin by combined microneedles and 
lipid microparticles. Int. J. Pharm., v.472, n.1-2, p.206-
213, 2014. 
PATNI, M.; PURANIK, P.; SONAWANE, A.; PANZADE, P. 
Transdermal iontophoretic delivery of timolol maleate. 
Braz. J. Pharm. Sci., v.48, n.4, p.819-827, 2012. 
PAŽOUREKOVÁ, S.; HOJEROVÁ, J.; KLIMOVÁ, Z.; 
LUCOVÁ, M. Dermal absorption and hydrolysis of 
methylparaben in different vehicles through intact and 
damaged skin: Using a pig-ear model in vitro. Food Chem. 
Toxicol., v.59, p.754-765, 2013. 
PEREIRA,  G.R. ;  COLLETT,  J .H. ;  GARCIA,  S .B. ; 
THOMAZINI, J.A.; VITÓRIA, M.; BADRA, L. Glycerol 
monooleate/solvents systems for progesterone transdermal 
delivery: Invitro permeation and microscopic studies. Rev. 
Bras. Ciênc. Farm.., v.38, n.1, p.55-62, 2002. 
PRAUSNITZ, M.R.; LANGER, R. Transdermal drug delivery. 
Nat. Biotechnol., v.26, n.11, p.1261-1268, 2009. 
REID, M.L.; BENAOUDA, F.; KHENGAR, R.; JONES, S.A.; 
BROWN, M.B. Topical corticosteroid delivery into human 
skin using hydrofluoroalkane metered dose aerosol sprays. 
Int. J. Pharm., v.452, n.1-2, p.157-165, 2013. 
REN, C.; FANG, L.; LING, L.; WANG, Q.; LIU, S.; ZHAO, 
L.; HE, Z. Design and in vivo evaluation of an indapamide 
transdermal patch. Int. J. Pharm., v.370, n.1-2, p.129-135, 
2009. 
ROBERTS, J.A.; ROBERTS, M.S.; ROBERTSON, T.A.; 
CROSS, S.E.; LIPMAN, J. A novel way to investigate the 
effects of plasma exchange on antibiotic levels: Use of 
microdialysis. Int. J. Antimicrob. Ag., v.31, n 3, p.240-244, 
2008. 
RUELA, A.L.M.; PEREIRA, G.R. Design and evaluation of 
molecularly imprinted polymers as drug delivery systems. 
In: TIWARI, A.; UZUN, L. (Eds.) Advanced molecularly 
imprinting materials. Beverly: Wiley-Scrivener, 2017. 
p.413-454.
RUELA, A.L.M.; FIGUEIREDO, E.C.; PEREIRA, G.R. 
Molecularly imprinted polymers as nicotine transdermal 
delivery systems. Chem. Eng. J., v.248, p.1-8, 2014. 
RUELA, A.L.M.; FIGUEIREDO, E.C.; PERISSINATO, 
A.G.; LIMA, A.C.Z.; PEREIRA, G.R. In vitro evaluation 
of transdermal nicotine delivery systems commercially 
available in Brazil. Braz. J. Pharm. Sci., v.49, n.3, p.579-
588, 2013. 
SALUJA, S.; KASHA, P.C.; PATURI, J.; ANDERSON, C.; 
MORRIS, R.; BANGA, A.K. A novel electronic skin patch 
for delivery and pharmacokinetic evaluation of donepezil 
following transdermal iontophoresis. Int. J. Pharm., v.453, 
n.2, p.395-399, 2013.
SCHNETZ, E.; FARTASCH, M. Microdialysis for the 
evaluation of penetration through the human skin barrier - a 
promising tool for future research? Eur. J. Pharm. Sci., v.12, 
n.3, p.165-174, 2001.
SCHWARZ, J.C.; PAGITSCH, E.; VALENTA, C. Comparison 
of ATR-FTIR spectra of porcine vaginal and buccal mucosa 
with ear skin and penetration analysis of drug and vehicle 
components into pig ear. Eur. J. Pharm. Sci., v.50, n.5, 
p.595-600, 2013.
SEKI, T.; WANG, A.; YUAN, D.; SASO, Y.; HOSOYA, O.; 
CHONO, S.; MORIMOTO, K. Excised porcine skin 
experimental systems to validate quantitative microdialysis 
methods for determination of drugs in skin after topical 
application. J. Control. Release, v.100, n.2, p.181-189, 
2004.
Evaluation of skin absorption of drugs from topical and transdermal formulations 543
SELZER, D.; ABDEL-MOTTALEB, M.M.A; HAHN, T.; 
SCHAEFER, U.F.; NEUMANN, D. Finite and infinite 
dosing: Difficulties in measurements, evaluations and 
predictions. Adv. Drug Deliv. Rev., v.65, n.2, p.278-294, 
2013. 
SHAH, S.M.; ASHTIKAR, M.; JAIN, A.S.; MAKHIJA, D.T.; 
NIKAM, Y.; GUDE, R.P.; STEINIGER, F.; JAGTAP, A.A.; 
NAGARSENKER, M.S.; FAHR, A. LeciPlex, invasomes, 
and liposomes: A skin penetration study. Int. J. Pharm., 
v.490, n.1-2, p.391-403, 2015.
SHANNON, R.J.; CARPENTER, K.L.H.; GUILFOYLE, M.R.; 
HELMY, A.; HUTCHINSON, P.J. Cerebral microdialysis in 
clinical studies of drugs: Pharmacokinetic applications. J. 
Pharmacokinet. Pharmacodyn., v.40, n.3, p.343-358, 2013. 
SHEARMAN, E.; ROSSI, S.; SZASZ, B.; JURANYI, Z.; 
FALLON, S.; POMARA, N.; SERSHEN, H.; LAJTHA, 
A. Changes in cerebral neurotransmitters and metabolites 
induced by acute donepezil and memantine administrations: 
A microdialysis study. Brain Res. Bull., v.69, n.2, p.204-
213, 2006.
SHINKAI, N.; KORENAGA, K.; OKUMURA, Y.; MIZU, H.; 
YAMAUCHI, H. Microdialysis assessment of percutaneous 
penetration of ketoprofen after transdermal administration 
to hairless rats and domestic pigs. Eur. J. Pharm. Biopharm., 
v.78, n.3, p.415-421, 2011.
SIEWERT, M.; DRESSMAN, J.; BROWN, C.K.; SHAH, V.P. 
FIP/AAPS Guidelines for dissolution/in vitro release testing 
of novel/special dosage forms. AAPS PharmSciTech, v.4, 
n.1, p.43-52, 2003. 
S N O R R A D Ó T T I R ,  B . S . ;  G U D N A S O N ,  P. I . ; 
THORSTEINSSON, F.; MÁSSON, M. Experimental 
design for optimizing drug release from silicone elastomer 
matrix and investigation of transdermal drug delivery. Eur. 
J. Pharm. Sci., v.42, n.5, p.559-567, 2011. 
SUBEDI, R.K.; RYOO, J.P.; MOON, C.; CHUN, M.K.; CHOI, 
H.K. Formulation and in vitro evaluation of transdermal 
drug delivery system for donepezil. J. Pharm. Investig., 
v.42, n.1, p.1-7, 2012. 
TANG, Z.; WANG, Q.; XU, H.; ZHANG, W. Microdialysis 
sampling for investigations of tetramethylpyrazine 
following transdermal and intraperitoneal administration. 
Eur. J. Pharm. Sci., v.50, n.3-4, p.454-458, 2013. 
TETTEY-AMLALO, R.N.O.; KANFER, I.; SKINNER, M.F.; 
BENFELDT, E.; VERBEECK, R.K. Application of dermal 
microdialysis for the evaluation of bioequivalence of a 
ketoprofen topical gel. Eur. J. Pharm. Sci., v.36, n.2-3, 
p.219-225, 2009.
THAKKER, K.; CHERN, W. Development and validation of in 
vitro release tests for semisolid dosage forms - Case study. 
Dissol. Technol., p.10-15, May, 2003. 
TOJO, K.; KESHARY, P.R.; CHIEN, Y.W. Drug permeation 
trhough skin from matrix-type drug delivery systems. Chem. 
Eng. J., v.32, n.3, p.B57-B64, 1986.
VALENTA, C.; AUNER, B.G. The use of polymers for dermal 
and transdermal delivery. Eur. J. Pharm. Biopharm., v.58, 
n.2, p.279-289, 2004. 
VICENTINI, F.T.M.C.; SIMI, T.R.M.; DEL CIAMPO, 
J.O.; WOLGA, N.O.; PITOL, D.L.; IYOMASA, M.M.; 
BENTLEY, M.V.L.B.; FONSECA, M.J.V. Quercetin in w/o 
microemulsion: In vitro and in vivo skin penetration and 
efficacy against UVB-induced skin damages evaluated in 
vivo. Eur. J. Pharm. Biopharm., v.69, n.3, p.948-957, 2008. 
WANG, K.; YAN, Y.; ZHAO, G.; XU, W.; DONG, K.; YOU, C.; 
ZHANG, L.; XING, J. In vitro and in vivo application of 
hydroxypropyl-β-cyclodextrin-grafted polyethyleneimine 
used as a transdermal penetration enhancer. Polym. Chem., 
v.5, n.16, p.4658-4669, 2014. 
WANG, Q.; MA, D.; HIGGINS, J.P. Drug product dissolution 
testing. Dissol. Technol., v.13, n.3, p.6-13, 2006. 
WILDING, I.R.; DAVIS, S.S.; RIMOY, G.H.; RUBIN, P.; 
KURIHARA-BERGSTROM, T.; TIPNIS, V.; BERNER, 
B.; NIGHTINGALE, J. Pharmacokinetic evaluation of 
transdermal buprenorphine in man. Int. J. Pharm., v.132, 
n.1-2, p.81-87, 1996.
WILLIAMS, A.C.; BARRY, B.W. Penetration enhancers. Adv. 
Drug Deliv. Rev., v.64, p.128-137, 2012.
WOKOVICH, A.M.; PRODDUTURI, S.; DOUB, W.H.; 
HUSSAIN, A.S.; BUHSE, L.F. Transdermal drug delivery 
system (TDDS) adhesion as a critical safety, efficacy and 
quality attribute. Eur. J. Pharm. Biopharm., v.64, n.1, p.1-
8, 2006. 
A. L. M. Ruela, A. G. Perissinato, M. E. S. Lino, P. S. Mudrik, G. R. Pereira544
WU, J.; PAUDEL, K.S.; STRASINGER, C.; HAMMELL, 
D.; STINCHCOMB, A.L.; HINDS, B.J. Programmable 
transdermal drug delivery of nicotine using carbon nanotube 
membranes. Proc. Natl. Acad. Sci. U. S. A., v.107, n.26, 
p.11698-11702, 2010. 
YAMASHITA, F.; HASHIDA, M. Mechanistic and empirical 
modeling of skin permeation of drugs. Adv. Drug Deliv. 
Rev., v.55, n.9, p.1185-1199, 2003. 
YANG, J.-A.; KIM, E.-S.; KWON, J.H.; KIM, H.; SHIN, J.H.; 
YUN, S.H.; CHOI, K.Y.; HAHN, S.K. Transdermal delivery 
of hyaluronic acid - Human growth hormone conjugate. 
Biomaterials, v.33, n.25, p.5947-5954, 2012. 
YANG, Y.; MANDA, P.; PAVURALA, N.; KHAN, M.A.; 
KRISHNAIAH, Y.S.R. Development and validation of in 
vitro-in vivo correlation (IVIVC) for estradiol transdermal 
drug delivery systems. J. Control. Rel., v.210, p.58-66, 
2015.
YE,  J .C . ;  ZENG,  S . ;  ZHENG,  G .L . ;  CHEN,  G .S . 
Pharmacokinetics of huperzine A after transdermal and 
oral administration in beagle dogs. Int. J. Pharm., v.356, 
n.1-2, p.187-192, 2008. 
ZHAN, X.; MAO, Z.; CHEN, S.; CHEN, S.; WANG, L. 
Formulation and evaluation of transdermal drug-delivery 
system of isosorbide dinitrate. Braz. J. Pharm. Sci., v.51, 
n.2, p.373-382, 2015. 
ZHANG, M.-Y.; HUGHES, Z.A.; KERNS, E.H.; LIN, Q.; 
BEYER, C.E. Development of a liquid chromatography/
tandem mass spectrometry method for the quantitation 
of acetylcholine and related neurotransmitters in brain 
microdialysis samples. J. Pharm. Biom. Anal., v.44, n.2, 
p.586-93, 2007.
ZHANG, Y.; CHAN, H.F.; LEONG, K.W. Advanced materials 
and processing for drug delivery: The past and the future. 
Adv. Drug Deliv. Rev., v.65, n.1, p.104-120, 2013.
ZHAO, X.; LIU, J.P.; ZHANG, X.; LI, Y. Enhancement of 
transdermal delivery of theophylline using microemulsion 
vehicle. Int. J. Pharm., v.327, n.1-2, p.58-64, 2006. 
ZORIN, S.; KUYLENSTIERNA, F.; THULIN, H. In vitro 
test of nicotine’s permeability through human skin. Risk 
evaluation and safety aspects. Ann. Occup. Hyg., v.43, n.6, 
p.405-413, 1999. 
Received for publication on 14th October 2015
Accepted for publication on 15th August 2016
